ZNF385A and hepatocellular carcinoma: Since ZNF385A was not tested in Hsu HCC cohort, we introduced the IMvigor210 cohort (a trial investigating the clinical activity of anti-PD-L1 atezolizumab in metastatic urothelial carcinoma) [21].